Clinical Trial Update: Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a conditioning regimen including bortezomib, total marrow irradiation, fludarabine phosphate, and melphalan for donor peripheral blood …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Fludarabine phosphate (Fludarabine phosphate)
• Melphalan (Melphalan)
• Total Marrow Irradiation

Snippet

Sponsor: City of Hope Medical Center | Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p | Phase 1 | Status: COMPLETED